CTNI-76. PHASE 2 CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM

Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated methylguanine DNA-methyltransferase (MGMT) promoter region, which confers a limited response to standard-of-care treatment with temozolomide (TMZ), resulting in shorter median survival when compared to patients with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Chen, Zhong-ping, Guo, Cheng-Cheng, Yang, Qun-ying, Wu, Shao-xiong, Li, Jia-Wei, Bacha, Jeffrey, Johnson, Greg, Langlands, John, Schwartz, Richard, Kwan, Claire, Kanekal, Sarath, Steino, Anne, Lopez, Lorena, Brown, Dennis
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Clinical Trials: Non-Immunologic
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651087/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.242
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia